(Q44840261)

6 December 2017

title

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis (English)

1 reference

6 December 2017

0 references

2

Björn Tackenberg

1 reference

6 December 2017

7

Christian Eienbröker

1 reference

6 December 2017

11

Tania Kümpfel

1 reference

6 December 2017

8

Ralf Gold

1 reference

6 December 2017

Joachim Havla

1

1 reference

6 December 2017

Kerstin Hellwig

3

1 reference

6 December 2017

Ingrid Meinl

4

1 reference

6 December 2017

Markus Krumbholz

5

1 reference

6 December 2017

Florian Seitz

6

1 reference

6 December 2017

Reinhard Hohlfeld

9

1 reference

6 December 2017

Ingo Kleiter

10

1 reference

6 December 2017

publication date

25 December 2012

1 reference

6 December 2017

1 reference

6 December 2017

volume

260

1 reference

6 December 2017

issue

5

1 reference

6 December 2017

page(s)

1382-1387

1 reference

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6808-8

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6808-8

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6808-8

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6808-8

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6808-8

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6808-8

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6808-8

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6808-8

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6808-8

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6808-8

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23266894

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23266894

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00415-012-6808-8

1 reference

6 December 2017

1 reference